Bioactivity-guided isolation of anti-adipogenic diarylpentanoids from Rhamnoneuron balansae.
Bian TT., Fan WN., Song XQ., Fan YY.
Animal Study, published in Fitoterapia (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Fitoterapia (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42229863
- DOI
- 10.1016/j.fitote.2026.107320
Abstract (original English)
A bioactivity-guided phytochemical investigation of Rhamnoneuron balansae led to the isolation of eight undescribed diarylpentanoids, named rhamnbalaoxy A-H (1-5, 13-15), along with seven known compounds (6-12). A key structural feature of these isolates is their shared diphenylpentane (C6-C5-C6) skeleton, and the diversity stems primarily from variations in the oxygenation and cyclization patterns of the central C5 unit. Notably, compounds 1 and 2 represent rare diarylpentanoid derivatives that incorporate a 2-phenylethylchromane moiety. Their structures were elucidated through comprehensive spectroscopic analysis, including HRESIMS and 1D/2D NMR, with their absolute configurations confirmed by experimental and calculated electronic circular dichroism (ECD) data. Bioactivity evaluation revealed that all compounds except 6 and 7 inhibited lipid accumulation in 3T3-L1 preadipocytes, demonstrating anti-adipogenic effects. Compound 15 demonstrated the highest potency, with an EC 50 value of 2.17 μM, about 3.3-fold lower than that of the positive control berberine (EC 50 = 7.24 μM). Mechanistic studies show that compound 15 inhibits adipogenesis by downregulating PPARγ, activates lipolysis by upregulating HSL and ATGL, and induces thermogenesis and metabolic reprogramming via FGF21 and UCP1.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.